Natus Medical Incorporated
NTUS · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $473 | $416 | $495 | $531 |
| % Growth | 13.9% | -16.1% | -6.7% | – |
| Cost of Goods Sold | $200 | $199 | $203 | $227 |
| Gross Profit | $274 | $217 | $292 | $304 |
| % Margin | 57.8% | 52.1% | 58.9% | 57.3% |
| R&D Expenses | $56 | $61 | $59 | $61 |
| G&A Expenses | $53 | $49 | $60 | $69 |
| SG&A Expenses | $169 | $156 | $189 | $205 |
| Sales & Mktg Exp. | $116 | $107 | $129 | $137 |
| Other Operating Expenses | $17 | $15 | $15 | $24 |
| Operating Expenses | $242 | $233 | $263 | $291 |
| Operating Income | $21 | -$20 | -$16 | -$25 |
| % Margin | 4.5% | -4.9% | -3.2% | -4.6% |
| Other Income/Exp. Net | -$2 | -$2 | -$6 | -$8 |
| Pre-Tax Income | $19 | -$22 | -$21 | -$32 |
| Tax Expense | $6 | -$5 | -$6 | -$9 |
| Net Income | $13 | -$17 | -$16 | -$23 |
| % Margin | 2.8% | -4% | -3.2% | -4.3% |
| EPS | 0.39 | -0.49 | -0.47 | -0.69 |
| % Growth | 179.6% | -4.3% | 31.9% | – |
| EPS Diluted | 0.39 | -0.49 | -0.47 | -0.69 |
| Weighted Avg Shares Out | 34 | 34 | 34 | 33 |
| Weighted Avg Shares Out Dil | 34 | 34 | 34 | 33 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $4 | $5 | $7 |
| Depreciation & Amortization | $28 | $28 | $31 | $34 |
| EBITDA | $49 | $10 | $14 | $8 |
| % Margin | 10.4% | 2.3% | 2.9% | 1.6% |